ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TNGX
ABCL (44) ARQT (54) LQDA (36) OGN (70) ⌘ Pro Terminal →

Tango Therapeutics Inc. (TNGX) — RQD Stock Rating Cockpit

$21.76 -4.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.55

Tango Therapeutics Inc. (TNGX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.83B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TNGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $21.76 (-4.22% 1D, market cap $3.83B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNGX ranks #358 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TNGX compare to ABCL and ARQT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, ABCL (AbCellera Biologics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -20.5%, cap $3.97B) and ARQT (Arcutis Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TNGX?
▼

Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $21.55 (-0.95%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C
Cash (5)Whales (10)SEC (14)Macro (11)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$36 Bull$20 Base$16 Bear
📬 FREE TNGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY TNGX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (31% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (24% of score)

FRED Regime × Technicals: 53% of 52W Range • RSI-14 at 46.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$22.19+21.6% Next Q
Q2 (-2Q)
50
Grade C-$26.98-17.6% Next Q
Q3 (-1Q)
48
Grade D$22.23-2.1% Next Q
Current
45
Grade D$21.76-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TNGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TNGX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.50) and Max Pain ($22.85) forces dealer call-delta covering toward $36.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TNGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE53% OF RANGE
L: $7$21.76H: $34
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on TNGX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-28.9% ROIC with 42.0% gross margin and -3.68% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (43)

15/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like TNGX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNGX)

  • ✓Walkthrough of TNGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.18%🛡️ HOLDING TREND SUPPORT
2026-11-03O $22.53H $22.72L $21.76C $21.76VOL 5.28M
RES: $28.20SUP: $20.48SMA50: $23.50SMA200: $22.48
$35.99$29.35$22.72$16.08$9.44RES $28.20SUP $20.48$21.762026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNGX Butterfly Map → + Track TNGX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
21.4%/yr Implied 5Y Growth

vs. +48.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TNGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNGX)

Health Care Rank #358 of 1015 ⚔️ ABCL vs TNGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNGX vs. ABCL, ARQT, LQDA, OGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Tango Therapeutics Inc. (TNGX) ranks #358 by composite RQD confidence (45/100, grade D) and #184 by equity capitalization ($3.83B). Within this direct 5-issuer industry benchmark cohort, OGN leads on earnings valuation at 19.4x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with TNGX at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TNGX ACTIVE
Tango Therapeutics Inc.
D 45/100 — — -28.9% -4.22% $3.83B Benchmark Subject
ABCL
AbCellera Biologics Inc.
D 44/100 — — -20.5% -9.37% $3.97B /abcl-vs-tngx →
ARQT
Arcutis Biotherapeutics Inc.
D+ 54/100 — 90.2% -3.0% -2.53% $4.03B /arqt-vs-tngx →
LQDA
Liquidia Corporation
D- 36/100 — — -12.6% -7.12% $4.03B /lqda-vs-tngx →
OGN
Organon & Co.
B- 70/100 19.4x 53.3% 24.9% -0.14% $3.63B /ogn-vs-tngx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819133 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tango Therapeutics Inc. (TNGX) reported GAAP revenue of $62.4M (+48.3% vs. FY2024 revenue of $42.1M , and +70.8% cumulative change since FY2023) , GAAP net income of -$101.6M, operating cash flow of -$138.9M, and free cash flow of -$139.9M (-5.8% YoY). On the balance sheet, TNGX closed FY2025 with $398.7M in total assets against $23.6M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $62.4M -$101.6M -$138.9M -$139.9M $398.7M $23.6M
FY2024 (FY) 2024-12-31 $42.1M -$130.3M -$131.5M -$132.3M $316.5M $52.6M
FY2023 (FY) 2023-12-31 $36.5M -$101.7M -$118.0M -$119.6M $2.09B $488.9M

3. TNGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $21.76 (-4.22% 1D, market cap $3.83B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNGX ranks #358 in composite RQD confidence.

How does TNGX compare to ABCL and ARQT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, ABCL (AbCellera Biologics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -20.5%, cap $3.97B) and ARQT (Arcutis Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TNGX?

Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TNGX trading relative to its 50-day, 200-day, and 52-week technical levels?

TNGX last traded at $21.76 (-4.22% on volume of 3,681,845 shares), positioning the stock -7.40% below its 50-day simple moving average ($23.50) and -3.20% below its 200-day simple moving average ($22.48). Across its 52-week range of $7.37 to $34.39, TNGX sits at the 53.3% percentile with a 14-day RSI of 46.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.04 to $24.48).

Direct Sub-Reports: TNGX RQD Cockpit TNGX 12M Forecast TNGX Earnings & Move TNGX Dividends & DRIP TNGX Insiders & 13F TNGX Whale Options TNGX Profit Sankey TNGX News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

TNGX — Tango Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Tango Therapeutics Inc. (TNGX) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $21.76 (-4.22% 1D, market capitalization $3.83B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -28.9%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -3.68%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (14/20): Incorporates a 0.87x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Tango Therapeutics Inc. (TNGX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It has a market capitalization of $3.8B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tango Therapeutics Inc. (TNGX) reported $62.4M in annual revenue (up from $42.1M in FY2024, +48.3% YoY) and -$101.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.5M revenue, -$101.7M net income) through FY2025, TNGX scaled operating cash flow to -$138.9M and free cash flow to -$139.9M, backed by $398.7M in total assets against $23.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.68% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $7.37 – $34.39 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TNGX carries a macro regime beta of 0.87 and gross margin of —.

  • Key Question #1: Can TNGX sustain or expand its -60.0% operating margin and -28.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $62.4M and free cash flow of -$139.9M, how will capital allocation balance growth reinvestment against $23.6M in total debt?
  • Key Question #3: How sensitive is TNGX's 28.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

TNGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tango Therapeutics Inc. (TNGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TNGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TNGX Bull vs. Bear Conversation Board — What's Your Call at $21.76?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TNGX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TNGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $28.63 (+26.0%)
📌 Pinned Debate

Revenue rose from $36.5M in FY 2023 to $62.4M in FY 2025 while total debt fell from $488.9M to $23.6M, and the Forensic Balance Sheet p

Long TNGX at $22.72 targeting $28.63. Revenue rose from $36.5M in FY 2023 to $62.4M in FY 2025 while total debt fell from $488.9M to $23.6M, and the Forensic Balance Sheet pillar scored 14/20 with Altman Z 26.. Institutional whale score is 10/20 and the risk/reward vs. the $7.37 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on 28.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $19.31 (-15.0%)
Spot @ $22.72

Free cash flow was -$139.9M in FY 2025 with ROIC at -28.9%, operating margin at -60%, and the Fundamental Cash Engine pillar scored onl

Fading this rally in TNGX at $22.72. Free cash flow was -$139.9M in FY 2025 with ROIC at -28.9%, operating margin at -60%, and the Fundamental Cash Engine pillar scored only 5/20.. With a beta of 0.87 and the stock sitting at $22.72 (52-wk range $7.37–$34.39), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%